Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00646
|
|||||
| Drug Name |
Chlorothiazide
|
|||||
| Synonyms |
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Aldoclor; Alurene; C 4911; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazide (JAN/USP/INN); Chlorothiazide [USAN:INN:BAN]; Chlorothiazidum; Chlorothiazidum [INN-Latin]; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazida [INN-Spanish]; Clorotiazide; Clorotiazide [DCIT]; Clotride; Component of Aldoclor; Diupres; Diuresal; Diuril; Diuril (TN); Diuril Boluses; Diuril Boluses, Veterinary; Diuril, Chlotride, Chlorothiazide; Diurilix; Diurite; Diutrid; Flumen; Minzil; Neo-Dema; Salisan; Salunil; Saluretil; Saluric; Sk-chlorothiazide; Thiazide; Urinex; Warduzide; Yadalan
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Edema associated with congestive heart failure [ICD11:BD10] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C7H6ClN3O4S2
|
|||||
| Canonical SMILES |
C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
|
|||||
| InChI |
InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
|
|||||
| InChIKey |
JBMKAUGHUNFTOL-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 58-94-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 295.7 | Topological Polar Surface Area | 135 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
-0.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321157
,10528492
,11110950
,11110951
,11335850
,11361089
,11363008
,11365570
,11368132
,11371323
,11373919
,11376294
,11462061
,11466279
,11467399
,11484024
,11486017
,11487970
,11490158
,11492095
,11493948
,15023005
,17389544
,17404817
,22425567
,24278150
,24714733
,26611653
,26680067
,26747285
,26747286
,29221877
,46507032
,47291140
,47291141
,47291142
,47515323
,47515324
,47662287
,47885422
,47959750
,48415760
,4970936
,5051008
,542598
,7847585
,7978922
,8149249
,855976
,9664
|
|||||
| ChEBI ID |
CHEBI:3640
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [3] | ||
| References | ||||||
| 1 | Chlorothiazide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53. | |||||
| 3 | Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.